Emerging anti-cancer antibodies and combination therapies targeting HER3/ ErbB3, Hum Vaccin Immunother, vol.12, pp.576-593, 2016. ,
Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res, vol.1, pp.1413-1420, 1995. ,
High expression of HER3 is associated with a decreased survival in gastric cancer, Clin Cancer Res, vol.14, pp.7843-7849, 2008. ,
Expression of c-erbB3 protein in primary breast carcinomas, Br J Cancer, vol.78, pp.1385-1390, 1998. ,
HER3 is a determinant for poor prognosis in melanoma, Clin Cancer Res, vol.14, pp.5188-5197, 2008. ,
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma, J Transl Med, vol.9, pp.126-136, 2011. ,
ErbB-3 predicts survival in ovarian cancer, J Clin Oncol, vol.24, pp.4317-4323, 2006. ,
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies, Cancer Cell, vol.20, pp.472-486, 2011. ,
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis, Sci Signal, vol.2, p.31, 2009. ,
Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer, Clin Cancer Res, vol.18, pp.956-968, 2012. ,
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines, Breast Cancer Res Treat, vol.134, pp.53-59, 2012. ,
,
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation, Cancer Res, vol.70, pp.2485-2494, 2010. ,
HER3 comes of age: new insights into its functions and role in signalling, tumor biology, and cancer therapy, Clin Cancer Res, vol.16, pp.1373-1383, 2010. ,
An activated ErbB3/ NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells, Cancer Cell, vol.17, pp.298-310, 2010. ,
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation, Neoplasia, vol.15, pp.335-347, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00815985
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer, Breast Cancer Res, vol.5, pp.8-15, 2003. ,
The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation, Nat Rev Mol Cell Biol, vol.12, pp.605-620, 2011. ,
E3 ubiquitin ligases in ErbB receptor quantity control, Semin Cell Dev Biol, vol.21, pp.936-943, 2010. ,
c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses, Biochem J, vol.391, pp.153-166, 2005. ,
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu, Proc Natl Acad Sci USA, vol.99, pp.12847-12852, 2002. ,
Earp HS 3rd. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signalling isoforms for degradation, Mol Cell Biol, vol.29, pp.892-906, 2009. ,
The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation, Faseb J, vol.21, pp.2849-2862, 2007. ,
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, Oncogene, vol.27, pp.3944-3956, 2008. ,
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR, Proc Natl Acad Sci USA, vol.110, pp.1815-1820, 2013. ,
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis, Proc Natl Acad Sci USA, vol.106, pp.3294-3299, 2009. ,
Inhibition of pancreatic carcinoma by homo-and heterocombinations of antibodies against EGFreceptor and its kin HER2/ErbB-2, Proc Natl Acad Sci USA, vol.110, pp.15389-15394, 2013. ,
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling, Proc Natl Acad Sci USA, vol.107, pp.13252-13257, 2010. ,
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy, Proc Natl Acad Sci USA, vol.102, pp.1915-1920, 2005. ,
Tumorinhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2, Cancer Res, vol.60, pp.3384-3388, 2000. ,
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody, Oncogene, vol.33, pp.34-43, 2014. ,
An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels, Proc Natl Acad Sci USA, vol.99, pp.2866-2871, 2002. ,
Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3, Proc Natl Acad Sci USA, vol.99, pp.14843-14848, 2002. ,
The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signalling, Oncogene, vol.34, pp.1105-1115, 2015. ,
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells, Biochem J, vol.447, pp.417-425, 2012. ,
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers, Cancer Res, vol.69, pp.4286-4293, 2009. ,
Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1, Mol Cell Biol, vol.3, pp.2180-2188, 2007. ,
Isoform-specific www.impactjournals.com/oncotarget monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms, Proc Natl Acad Sci USA, vol.105, pp.4162-4167, 2008. ,
Nedd4 mediates ErbB4 JM-a/ CYT-1 ICD ubiquitination and degradation in MDCK II cells, Faseb J, vol.23, pp.1935-1945, 2009. ,
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change, Proc Natl Acad Sci USA, vol.103, pp.1717-1722, 2006. ,
Itch self-polyubiquitylation occurs through lysine-63 linkages, Biochem Pharmacol, vol.76, pp.1515-1521, 2008. ,
The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch, Proc Natl Acad Sci USA, vol.104, pp.11280-11285, 2007. ,
Itch WW Domains Inhibit Its E3 Ubiquitin Ligase Activity by Blocking E2-E3 Ligase Trans-thiolation, J Biol Chem, vol.290, pp.23875-23887, 2015. ,
Regulation of Itch and Nedd4 E3 Ligase Activity and Degradation by LRAD3, Biochemistry, vol.55, pp.1204-1213, 2016. ,
WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer, Oncogene, vol.28, pp.2948-2958, 2009. ,
Ubiquitin-specific protease 8 links the PTENAkt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme, Cancer Res, vol.70, pp.5046-5053, 2010. ,
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma, Nature, vol.486, pp.266-270, 2012. ,
The ubiquitin ligase itch is autoubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X, J Biol Chem, vol.28, pp.38738-38747, 2006. ,
Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8, Mol Cell Biol, vol.24, pp.7748-7757, 2004. ,
Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma, Cancer Biol Ther, vol.15, pp.1042-1052, 2014. ,
Examination of HER3 targeting in cancer using monoclonal antibodies, Proc Natl Acad Sci USA, vol.112, pp.839-844, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02276327
Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor, J Oral Pathol Med, vol.43, pp.250-257, 2014. ,
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling, Oncogene, vol.31, pp.1275-1286, 2012. ,
Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells, Cell Cycle, vol.11, pp.1455-1467, 2012. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00961644
Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor, Int J Cancer, vol.124, pp.2281-2293, 2009. ,
Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation, J Clin Oncol, vol.33, p.289, 2015. ,
Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth, Breast Cancer Res, vol.17, p.20, 2015. ,
Degradation of p63 by Itch, Cell Cycle, vol.5, pp.1735-1739, 2006. ,
The ubiquitin-protein ligase Itch regulates p73 stability, Embo J, vol.24, pp.836-848, 2005. ,
The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor, Mol Cell Biol, vol.23, pp.3363-3372, 2003. ,
Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3, Protein Sci, vol.16, pp.654-661, 2007. ,
An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells, Cell Res, vol.19, pp.984-995, 2009. ,
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal www.impactjournals.com/oncotarget antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways, Blood, vol.115, pp.5180-5190, 2010. ,
The HECT domain ligase itch ubiquitinates endophilin and localizes to the trans-Golgi network and endosomal system, J Biol Chem, vol.279, pp.11471-11479, 2004. ,
Novel roles for the E3 ubiquitin ligase atrophin-interacting protein 4 and signal transduction adaptor molecule 1 in G protein-coupled receptor signalling, J Biol Chem, vol.287, pp.9013-9027, 2012. ,
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models, Oncotarget, vol.5, pp.7138-7148, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01075330